Judge Says Janssen Alzheimer's Patent Invalid

Law360, New York (August 28, 2008, 12:00 AM EDT) -- A federal judge has ruled that Janssen Pharmaceutica Inc.'s Alzheimer's drug patent is invalid for lack of enablement in a victory for several generic-drug makers accused of infringing the patent.

Judge Sue Robinson ruled against Janssen in the U.S. District Court for the District of Delaware in a consolidated case the company had filed against several generics makers over Alzheimer's drug Razadyne.

In 2005, the defendant drug companies filed abbreviated new drug applications with the U.S. Food and Drug Administration to make generic versions of the...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.